Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Horlicks Review Plan - Some Early Expectations In India

Executive Summary

A potential sale of Horlicks could impact market dynamics significantly in India where the popular malt beverage holds a dominant position but has seen competition build up. GlaxoSmithKline, though, has underscored that the review plan had nothing to do with the product’s "critical mass".
Advertisement

Related Content

GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business
GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business
GSK Divesting Horlicks Nutritional Business, Investing In OTC Production
Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market
GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy
GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes
Reckitt At '2.0' On Consumer Expansion But Question No. 1 Remains, Potential Pfizer Business Bid?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100647

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel